Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  St Jude Medical Inc    STJ

ST JUDE MEDICAL INC (STJ)
Mes dernières consult.
Most popular
Report
SummaryQuotesNewsCompany 
News SummaryMost relevantAll newsSector newsTweets

St. Jude Medical, Inc. : Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against St. Jude Medical, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/11/2012 | 12:15am CET

Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the District of Minnesota on behalf of all persons or entities that purchased the common stock of St. Jude Medical, Inc. ("St. Jude" or the "Company") (NYSE: STJ) between October 17, 2012 and November 20, 2012, inclusive (the "Class Period"), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the "Complaint").

If you purchased shares of St. Jude during the Class Period, or purchased shares prior to the Class Period and still hold St. Jude, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to info@rigrodskylong.com, or at: http://www.rigrodskylong.com/investigations/st-jude-medical-inc-stj-durata.

St. Jude, a Minnesota corporation headquartered in St. Paul, Minnesota, develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company's business, operations and prospects. Specifically, the Complaint alleges that the Defendants concealed relevant information from the investment community relating to a report issued by the United States Food and Drug Administration ("FDA") for one of its chief products, the Durata defibrillation lead. As a result of defendants' false and misleading statements, the Company's stock traded at artificially inflated prices during the Class Period. Capitalizing on this was the Company's Chief Executive Officer, Daniel J. Starks, who took advantage of the artificially inflated prices of St. Jude stock, and sold 200,000 shares for proceeds totaling more than $7.6 million.

According to the Complaint, the Company stated during an October 17, 2012 earnings call that a St. Jude production facility located in Sylmar, California was undergoing an FDA inspection. This inspection was expected to generate the issuance of a "Form 483" - a form used by FDA investigators to list observations of objectionable conditions found during the course of an inspection. On October 24, 2012, the Company filed a Form 8-K with the United States Securities and Exchange Commission ("SEC"), attaching a heavily redacted version of the Form 483 issued by the FDA. The version released by the Company fails to include any product name associated with the inspection results.

However, on November 20, 2012, the FDA released its own version of the Form 483 for its inspection of the Sylmar facility. The version released by the FDA, while still redacted, nevertheless showed clearly that most of the observations of objectionable conditions listed on the form pertained to Durata. Despite knowing that most of the inspection report concerned issues pertaining to Durata, the defendants chose to conceal this information from the investing public by issuing the heavily redacted version. On this news, shares in St. Jude declined 12%, from a close of $35.71 per share on November 20, 2012 to $31.37 per share on November 21, 2012, on volume of over 26 million shares.

If you wish to serve as lead plaintiff, you must move the Court no later than February 5, 2013. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

While Rigrodsky & Long, P.A. did not file the Complaint in this matter, the firm, with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky & Long, P.A.
Timothy J. MacFall, Esquire
Peter Allocco
888-969-4242
516-683-3516
Fax: 302-654-7530
info@rigrodskylong.com
http://www.rigrodskylong.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ST JUDE MEDICAL INC
11/22 ST JUDE MEDICAL : $12,244 Federal Contract Awarded to St. Jude Medical
11/09 ST JUDE MEDICAL : Federal Contracts Awarded by Federal Agencies in Indiana (Nov...
11/09 ST JUDE MEDICAL : Federal Contracts Awarded to Companies in Minnesota (Nov. 9)
11/09 ST JUDE MEDICAL : $35,241 Federal Contract Awarded to St. Jude Medical
11/03 ST JUDE MEDICAL : 65-- VAAAHS St. Judes HV IDIQ
11/01 ST JUDE MEDICAL : Twiddler’s syndrome presenting as life threatening elect..
10/20 ABBOTT LABORATORIES : Reports Third Quarter 2017 Results
06/01 ST JUDE MEDICAL : Patent Issued for Surgical Heart Valve Flexible Stent Frame St..
06/01 ST JUDE MEDICAL : "Leaflet-Cuff Attachments for Prosthetic Heart Valve" in Paten..
05/25 ST JUDE MEDICAL : Patent Issued for Catheter with Atraumatic Tip (USPTO 9649155)
More news
News from SeekingAlpha
04/27 DIVIDEND STREAKS IN DANGER : 2016 Review And 2017 Preview
04/18 Abbott-Alere Deal To Go Ahead
02/17 GLAZER CAPITAL : Merger Arbitrage With Convertibles - A Lower Risk Alternative
02/15 Panel To Stand Sentinel Over Embolic Filter
02/01 Dividend Champions For February 2017
Managers
NameTitle
Michael T. Rousseau President, Chief Executive Officer & Director
Scott P. Thome Vice President-Global Operations & Supply Chain
Mark D. Carlson Chief Medical Officer & VP-Global Clinical Affairs
Mark W. Murphy Chief Information Officer & Vice President-IT
Philip J. Ebeling Chief Technology Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ST JUDE MEDICAL INC0.79%0
STRYKER CORPORATION29.20%57 928
SMITH & NEPHEW8.03%15 534
WRIGHT MEDICAL GROUP NV7.35%2 591
JAPAN LIFELINE CO., LTD.115.27%2 018
GLAUKOS CORP-28.57%847